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Abstract Human lysosomal acid lipase (LAL), when expressed 
in HeLa cells using the Vaccinia T7 expression system, showed 
four major molecular forms ranging from 42 to 54 kDa. 
Treatment with endoglyeosidase H resulted in a 42 kDa protein, 
indicating that the molecular weight variations were due to N- 
glycosylation. A missense substitution, L273S, previously 
detected in a patient with eholesteryl ester storage disease 
(CESD), produced catalytically inactive LAL showing a largest 
molecular mass form of 56 kDa instead of 54 kDa. Analysis of 
the amino acid sequence in the close proximity of the mutation 
(NMS ~ NML) indicated that the L273S mutation creates an 
additional N-glycosylation consensus (N-X-S/T) in this region. 
Two site directed mutants disrupting this consensus, QMS and 
QML, when expressed in HeLa cells, did not show the 56 kDa 
form but the normal 54 kDa band whereas deglyeosylation 
always resulted in the major 42 kDa form, as observed with 
normal LAL and the L273S mutant. These data confirmed that 
an additional N-glycosylation at N271 was responsible for the 56 
kDa form of the protein produced from the L273S allele. 
Furthermore, deglycosylation of normal LAL reduced the acid 
hydrolase activity towards both tri-oleyl glycerol and eholesteryl 
oleate by 50%, strongly suggesting that N-linked carbohydrate 
residues are important for optimal catalytic activity. 
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1. Introduction 
Hydrolysis of cholesteryl esters ~tnd triglycerides, delivered 
to the lysosomes through the receptor mediated endocytosis of 
lipoprotein particles, is exclusively mediated by lysosomal acid 
lipase (LAL) [1]. The amino acid composition of LAL, de- 
rived from the cloned cDNA sequence, predicts a 378 amino 
acid polypeptide chain with an estimated molecular mass of 
42.5 kDa [611. The primary amino acid sequence of LAL sug- 
gests the possibility of a 27 amino acid N-terminal signal 
peptide and six consensus N-glycosylation (N-X-S/T) sites. 
Three of these consensus ites, at N15, N80 and N252, are 
conserved among the members of the acid lipase gene family 
including rat lingual lipase and human gastric lipase [6]. The 
presence of N-glycosylation signals within the LAL primary 
structure indicates mannose-6-phosphate receptor mediated 
specific targeting to the lysosomal compartment [1,2]. 
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Acid lipase deficiency is associated with two autosomal re- 
cessive, lysosomal storage disorders, cholesteryl ester storage 
disease (CESD) and Wolman disease [1], both characterized 
by a massive accumulation of cholesteryl esters and triglycer- 
ides in different issues of the body including liver, spleen and 
adrenals. The most severe form of the disease, Wolman's dis- 
ease, is lethal during the first year of life, while CESD follows 
a more benign clinical course frequently characterized by dis- 
lipidemia nd hepatomegaly during childhood. A low residual 
activity of LAL has been suggested to be responsible for the 
different phenotypic expression of CESD and Wolman disease 
[1,7]. 
Different mutations in the LAL gene have been reported in 
patients with CESD and Wolman disease [8-13]. We have 
recently described the molecular basis of CESD in three pa- 
tients with the identification of three different missense sub- 
stitutions, two splicing defects that do not alter the open read- 
ing frame and a null allele [14]. One of these patients was a 
compound heterozygote for a missense substitution (L273S) 
and a null allele. 
The very low amount of LAL that can be isolated from 
mammalian cells has limited its extensive characterization. 
Different molecular sizes have been reported for purified hu- 
man LAL. A 47 kDa form was reported to be secreted from 
fibroblasts [2], and two forms of 56 and 41 kDa were purified 
from human liver [3]. On the other hand, two molecular forms 
of 46 and 41 kDa have been reported for human LAL ex- 
pressed in insect cells, a system in which the targeting of 
lysosomal enzymes is not regulated by the canonical mamma- 
lian mannose-6-phosphate receptor [4,5]. The origin of the 
different molecular mass forms of LAL is not yet clear, while 
both selective proteolysis and N-glycosylation have been sug- 
gested to be responsible for their occurrence. Discrepancies in
the results might be due to biased purification procedures or 
the type of expression system employed [2-4], particularly 
considering that very little is known about the glycosylation 
pattern of mutant LALs and the effect of glycosylation on 
their catalytic activity. 
In this report, we have evaluated the effect of the missense 
substitution L273S on the glycosylation pattern of recombi- 
nant LAL protein. In addition, we have examined the general 
effect of glycosylation on the enzymatic activity of LAL. 
2. Materials and methods 
2.1. PCR amplification and oligonucleotides 
The sequences of the oligonucleotides used for mutagenesis are 
listed on the following page.PCR amplifications were performed ac- 
cording to Saiki et al. [15] using Taq polymerase (Boehringer Mann- 
heim), with 50 pM of each corresponding set of oligonucleotides and 
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LALF782TGCACTCATGTCATACTGAA 
LAUlrevACCTCCGCCAGATCCCTGATATTTCCTCATTAGA 
QS1 AACAGATGTCACACTGGAGCCAG 
QS2 TGTGACATCTGTTGCACAGAAGT 
QL1 AACAGATGTTACACTGGAGCCAG 
QL2 TGTAACATCTGTTGCACAGAAGT 
was performed for 2 h at 200 mA. After transfer, the membranes were 
stained with Ponceau Red S, washed and blocked for 1 h in TBS 
containing 5% skimmed milk. Tag antigens were detected using 
anti-HSVtag monoclonal antibody (Novagen, Madison, WI) followed 
by an alkaline phosphatase-conjugated goat anti-mouse IgG. 
5 U of Taq polymerase for 35 cycles (45 s at 93°C, 60 s at 52°C and 
90 s at 72°C). 
2.2. Construction of HSV tagged LAL mutants by site directed 
mutagenesis 
Normal (pLALtag) and mutant LALs were tagged with a 11 amino 
acid peptide (QPELAPEDPED) derived from herpes simplex virus 
glycoprotein D. This peptide was linked to the carboxyl end of 
LAL by a 5 amino acid connecting segment (GSGGG) using the 
PCR- based overlap extension method [16]. Two site directed mutants 
at residues 271 273, QML and QMS, were constructed using the same 
technique. The central portion of pLALtag, between the SacI and 
AccI restriction sites, was substituted with the mutagenized amplified 
fragments, pLALtag was amplified with primer pairs LALF782/QS1 
or QL1 and LALJlrev/QS2 or QL2. The two corresponding frag- 
ments were mixed and reamplified with LALF782/LALJlrev. The 
product of the second PCR was digested with Sac| and AccI restric- 
tion endonucleases and recloned in pLALtag. The resulting plasmid 
DNAs, purified on miniprep Spun Columns (Pharmacia Biotech, Swe- 
den), were sequenced according to the dideoxy chain terminating 
method using [et-3SS]dATP and recombinant T7 DNA polymerase 
(Pharmacia Biotech, Sweden) [17,18]. 
2.3. Expression of LAL mutants 
Expression of LAL by means of the Vaccinia T7 expression system 
was performed according to [19]. Recombinant Vaccinia virus vTF7-3, 
bearing the bacteriophage T7 1 gene, was a generous gift of T. Fuerst 
and B. Moss [19]. HeLa cells grown in Dulbecco's modified Eagle 
medium containing 10% fetal bovine serum were infected with 
vTF7-3 at a multiplicity of 30 plaque-forming units per cell, in se- 
rum-free medium. The virus was removed after 30 min incubation at 
37°C and replaced with serum-free medium. Cells were transfected 
with 2.8 lag of each LAL plasmid DNA plus 0.2 lag of a CAT expres- 
sing plasmid (pULB), complexed with 20 lag of cationic liposome 
DOTAP (Boehringer Mannheim). The control transfection was per- 
formed with pULB plasmid alone. Cells were harvested 16 24 h after 
infection-transfection. Cell pellets were resuspended with 0.16 ml of 
100 mM sodium acetate buffer (pH 4.8) containing the protease in- 
hibitors leupeptin (15 ~tg/ml), aprotinin (15 lag/ml), pepstatin (5 lag/ 
ml), PMSF (0.25 raM) and EGTA (0.7 mM), at 0°C. 
2.4. Endoglycosidase treatment and measurement ofacid lipase activity 
Cell extracts were prepared by sonication for 10 s at an amplitude 
of 10 lam (Soniprep150, MSE) with the subsequent addition of Triton 
X-100 (0.2% w/v final concentration). Cell extracts were incubated at 
37°C with or without 50 mU of endoglycosidase H (Boehringer 
Mannheim), for 12 h. Aliquots of each sample were subjected to 
immunoblotting and assayed for acid lipase activity. 
The reaction for the measurement of acid lipase activity mixtures 
contained cell extract (3~50/ag of protein), 100 mM sodium acetate 
buffer (pH 4.8), 0.2% (w/v) Triton X-100 and either cholesteryl- 
[:4C]oleate (0.2 mM, 5 laCi/ml) or tri-[14C]oleyl-glycerol (0.3 raM, 
5 laCi/ml), in a total volume of 0.1 ml. After incubation at 37°C for 
30 min, the reaction product ([14C]oleate) was separated by extraction 
of the reaction mixtures with benzene-chloroform-methanol (10:5:12 
v/v/v) containing 0.3 mM oleic acid, as described by Pittman et al. 
[20]. The aqueous upper phases containing the partitioned [14C]oleate 
were counted for 13-radioactivity. Cholesteryl oleate and tri-oleyl- 
glycerol hydrolase activities are expressed as pmol of [HC]oleate re- 
leased/lag of protein/h. 
2.5. lmmunoblotting 
SDS-PAGE was performed according to the method of Laemmli 
[21]. Extracts of HeLa cells (40 lag protein) expressing normal or 
mutant LALs were resuspended in denaturing sample buffer contain- 
ing 4% SDS and 3% dithiothreitol. After 5 min at 100°C the samples 
were loaded onto 12% polyacrylamide g ls and subjected to electro- 
phoresis. Western blotting of the proteins to nitrocellulose membranes 
3. Results and discussion 
Since LAL is ubiquitously expressed [1], in this study trans- 
fected LALs were distinguished from the endogenous one by 
tagging at the carboxyl terminus with a herpes simplex virus 
epitope of 11 amino acids (Fig. 1). At the same time, the 
endogenous acid lipase activity was reduced by the recombi- 
nant Vaccinia virus infection used to enhance the expression 
of transfected LALs. Normal LAL expressed in HeLa cells 
using this system showed four major molecular forms of 54, 
50-51, 43 and 42 kDa (Fig. 2, LAL). The expression of the 
L273S CESD allele resulted in a different pattern of expres- 
sion, showing the presence of a larger molecular mass form of 
56 kDa (Fig. 2, L273S). 
Careful examination of the amino acid sequence in the vi- 
cinity of the mutation revealed that the leucine to serine sub- 
stitution at position 273 creates a new consensus for N-glyco- 
sylation at asparagine residue 271 (Fig. 1) that could account 
for the higher molecular weight form of the protein expressed 
by this mutant. In order to verify this possibility, two site 
directed mutants were constructed. The asparagine at position 
271 was replaced with glutamine keeping leucine or serine at 
position 273 (QML and QMS, Fig. 1). Expression of these 
mutants in HeLa cells resulted in the same pattern of Mr 
forms as the normal LAL (Fig. 2, QMS and QML). The 
absence of the 56 kDa form in QMS confirms that the serine 
of L273S per se is not responsible for the 56 kDa protein and 
strengthens the view that an oligosaccharide chain linked to 
the asparagine at position 271 is responsible for the higher 
molecular mass of the L273S mutant protein. 
Although it is known that N-linked glycosylation is impor- 
tant for lysosomal targeting of LAL via the mannose-6-phos- 
phate receptor, its involvement in the generation of the differ- 
ent molecular forms of LAL expressed in mammalian cells has 
not been investigated. In order to determine the glycosylation 
status of these forms, extracts of cells transfected with normal 
T7 LAL spacer )ag 
266 -"" "- 278 
LAL GTSVQNMLHWSQA 
L273S GTSVQNMSHWSQA 
QMS GTSVQQMSHWSQA 
QML GTSVQQMLHWSQA 
Fig. I. Schematic representation f the LAL constructs used in the 
Vaccinia T7 expression system. Normal and mutant LALs, cloned 
under the T7 promoter, were extended at the 3' end with a 5 amino 
acid spacer egion (black box) followed by an 11 amino acid stretch 
from the HSV epitope tag (gray box). The expanded amino acid re- 
gion between residues 266 and 278 of human lysosomal acid lipase 
shows the position of the amino acid changes in the CESD allele 
(L273S) and in the site directed mutants. The leucine to serine sub- 
stitution in L273S creates a new consensus N-glycosylation site (un- 
derlined). 
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Fig. 2. lmmunoblots of normal and mutant LALs expressed in HeLa cells before and after treatment with endoglycosidase H. The 56 kDa 
form expressed by L273S mutant is indicated by the arrow head. It can be noted that this band is also reduced to 42 kDa form after endogly- 
cosidase H treatment (L273S, Endo H+) just as the 54 kDa form of normal LAL and QMS/QML mutants. 
LAL and the different mutants were treated with endoglyco- 
sidase H. In the case of normal LAL, a major 42 kDa form 
was detected after digestion with endoglycosidase H (Fig. 2, 
LAL endo+). This indicates that the larger molecular forms of 
54 and 50 51 kDa represent completely and partially glyco- 
sylated forms respectively, whereas the smaller 42 kDa band 
represents the non-glycosylated form. Similarly, the 42 kDa 
form was present in all the other mutants after treatment with 
endoglycosidase H. It should be noted that the 56 kDa form 
of L273S was also reduced to the smaller 42 kDa form, in- 
dicating that the increase from 54 to 56 kDa was due to 
additional glycosylation. The same results were obtained after 
deglycosylation with PNgase F (data not shown). In view of 
these results, it is plausible that all the 6 putative N-glycosyla- 
tion sites of LAL could be occupied by carbohydrate chains 
contributing an average of 2 kDa to the molecular weight of 
the protein. 
The influence of glycosylation on the catalytic activity of 
LAL was investigated by measuring the acid cholesteryl ester- 
ase and triacylglycerol hydrolase activities in the extracts of 
HeLa cells infected and transfected with normal and mutated 
LALs, with and without endoglycosidase H treatment. Trans- 
fection with normal LAL increased both activities 8-10 times 
above the control (90 + 10 pmol/~tg/h for triacylglycerol hy- 
drolase and 30 + 5 pmol/gg/h for cholesteryl esterase). Endo- 
glycosidase H treatment of the extracts reduced both choles- 
teryl esterase and triacylglycerol hydrolase activities by 
approximately 50'¼, (Fig. 3, LAL Endo H +/ - )  compared to 
the control extracts incubated in the same way but in the 
absence of endoglycosidase H. On the contrary, transfection 
with the L273S CESD allele and the site directed mutants 
(QMS, QML) showed both activities at background control 
levels (Fig. 3, QML, QMS Endo H +/-) .  The absence of 
activity of QMS and QML indicates that the asparagine r s- 
idue at position 271 plays an important role concerning the 
formation of an active conformer, probably independent of
glycosylation. 
Previous tudies have analyzed the involvement of glycosyl- 
ation in the catalytic activity of LAL, with contradictory 
results. Expression of human LAL in Sf9 insect cells produced 
two molecular forms of 41 and 46 kDa and only the higher, 
glycosylated form was suggested to be active [4]. However, 
expression of highly glycosylated proteins in this heterologous 
system does not seem convenient to study the processing of 
lysosomal enzymes as these cells produce an aberrant pattern 
of glycosylation and do not follow the typical mammalian 
mannose-6-phosphate rec ptor pathway for lysosomal target- 
ing [5]. The relative abundance of inactive, non-glycosylated 
E 
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Fig. 3. Acid lipase activity of Vaccinia infected HeLa cells trans- 
fected with normal and mutated LALs. The effect of deglycosylation 
on enzymatic activity is indicated. Each value represents he 
mean + S.D. of three independent experiments. 
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41 kDa form reported in this case may indeed reflect the 
abnormal processing of LAL in insect cells. 
Two major forms of LAL of 56 and 41 kDa, similar to the 
recombinant proteins we have detected in HeLa cells with the 
Vaccinia T7 system, have been purified from human liver [3]. 
Partial amino acid sequencing of these two hepatic forms 
suggested that the 56 kDa form is a precursor protein from 
which 49 amino acids are cleaved off from the N-terminus 
yielding a mature LAL protein. The presence of N-linked 
carbohydrate residues was investigated only in the case of 
the 41 kDa form, showing a reduction of approximately 5 
kDa after deglycosylation [3]. 
Our experiments indicate that the size heterogeneity of LAL 
expressed in HeLa cells is completely due to N-glycosylation, 
as endoglycosidase H treatment always resulted in a major 42 
kDa form (Fig. 2). Expression of a LAL construct lacking the 
N-terminal 49 amino acids resulted in a catalytically inactive, 
non-glycosylated protein of 37 kDa that could be easily dif- 
ferentiated from the 42 kDa form by the electrophoretic mo- 
bility (data not shown). We do not have amino acid sequence 
information about the lower molecular mass forms of LAL 
observed in HeLa cells. However, our expression studies 
clearly indicate that proteolytic processing is not involved in 
the maturation of the N-terminus of LAL or, alternatively, 
that the N-terminal proteolysis is tissue specific and occurs in 
hepatocytes but not in HeLa cells. It will be necessary to 
express LAL in different cell types in order to verify whether 
such a tissue-specific processing exists. 
The 50% reduction in both cholesteryl esterase and triacyl- 
glycerol hydrolase activities following deglycosylation suggests 
that N-linked carbohydrate residues, although not essential 
for LAL activity, may have an important role in the main- 
tenance or stabilization of a fully active conformation. 
Changes in the tertiary structure of non-glycosylated LAL 
might interfere with the lipid binding of the enzyme or the 
structure of the active site, consequently reducing the effi- 
ciency of catalysis. 
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